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Abstract: Rabbit haemorrhagic disease virus (RHDV) is a calicivirus that causes acute infections
in both domestic and wild European rabbits (Oryctolagus cuniculus). The virus causes significant
economic losses in rabbit farming and reduces wild rabbit populations. The recent emergence of
RHDV variants capable of overcoming immunity to other strains emphasises the need to develop
universally effective antivirals to enable quick responses during outbreaks until new vaccines become
available. The RNA-dependent RNA polymerase (RdRp) is a primary target for the development
of such antiviral drugs. In this study, we used cell-free in vitro assays to examine the biochemical
characteristics of two rabbit calicivirus RdRps and the effects of several antivirals that were previously
identified as human norovirus RdRp inhibitors. The non-nucleoside inhibitor NIC02 was identified
as a potential scaffold for further drug development against rabbit caliciviruses. Our experiments
revealed an unusually high temperature optimum (between 40 and 45 ˝C) for RdRps derived from
both a pathogenic and a non-pathogenic rabbit calicivirus, possibly demonstrating an adaptation to a
host with a physiological body temperature of more than 38 ˝C. Interestingly, the in vitro polymerase
activity of the non-pathogenic calicivirus RdRp was at least two times higher than that of the RdRp
of the highly virulent RHDV.
Keywords: RHDV; RCV-A1; polymerase; non-nucleoside inhibitors; antiviral agents
1. Introduction
Rabbit haemorrhagic disease (RHD) is a highly infectious disease with high case fatality and
morbidity rates in adult rabbits. The incubation period ranges between 1 and 3 days and rabbits usually
die within 12–36 h after the onset of fever, which is not always observed [1–3]. The primary target
organs for RHD are the liver, lungs and the spleen, with involvement of the resident macrophages [4].
The major histopathological features of RHD include acute hepatitis and splenomegaly. Haemorrhages
and congestions can be found in a variety of organs, particularly in the lungs, heart and kidneys,
as a result of massive disseminated intravascular coagulation [1,5]. Rabbit haemorrhagic disease
virus (RHDV) infection in rabbits causes severe leukopenia, involving B and T lymphocytes [6,7], and
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granulocytes [6]. Depletion of peripheral blood leucocytes and lymphocytes in the liver and spleen
accompanies the disease and is associated with apoptosis [7,8].
RHD was first detected in China in 1984 [3] and subsequently disease outbreaks were reported
from most continents and in many countries, including Korea, Italy, Spain, Portugal, France, United
Kingdom, Mexico, North America, Cuba, several countries in Africa and elsewhere (reviewed in [2]). In
the Iberian Peninsula, where European rabbits originated and where they constitute a keystone species
of the ecosystem, RHD caused and continues to cause severe reductions of wild rabbit populations.
This in turn has affected many predator species, e.g. the critically endangered Spanish imperial eagle
and the Iberian lynx [9,10]. The real impact of RHD on local ecosystems can be much greater, since
rabbits alter plant species composition and vegetation structure through grazing and seed dispersal [9].
In Australia and New Zealand, RHDV has been utilized since the mid-1990s as a biological control
agent for rabbits, a serious pest in these countries, resulting in substantial benefits to agricultural
industries and the environment [11,12].
RHDV is a single-stranded positive-sense RNA virus [2,13,14] that belongs to the family
Caliciviridae, genus Lagovirus [15,16]. Its RNA is tightly packaged into non-enveloped icosahedral
capsids that consist of 180 VP60 proteins [2,17]. The 35-nm virions contain 7.4 kb of genomic RNA
and additional 2.1 kb fragments of subgenomic RNA that are collinear with the 3’ end of the genomic
RNA [14,18,19]. Both genomic and subgenomic viral RNAs are polyadenylated at the 3’ end [2]
and covalently linked to the genome binding protein (VPg) at the 5’ end [2,19,20]. The genomic
RNA contains two slightly overlapping reading frames (ORF) of 7 kb (ORF1) and 351 nucleotides
(ORF2) [13,14]. ORF1 is translated into a large polyprotein that is cleaved into several non-structural
proteins and the major structural protein, the capsid protein [13,18,21]. ORF2 encodes a minor
structural protein, VP10 [2,13]. The subgenomic RNA only encodes both the structural proteins,
VP60 [2,22] and VP10 [2]. The RHDV genome encodes a total of at least nine proteins [13,18];
comprising the helicase, the VPg protein, the protease, the RNA-dependent RNA polymerase (RdRp),
the capsid protein VP60, the VP10 protein and three proteins of unknown function, p16, p23 and
p29 [2,13,18,23].
The emergence of RHDV from a pre-existing non-pathogenic rabbit calicivirus that became a
lethal pathogen by mutation and subsequently spread around the world, has been suggested [24].
Indeed benign rabbit caliciviruses (RCVs), which are non-pathogenic relatives of RHDV, have been
discovered in Australia [25] and several European countries [26,27]. In contrast to RHDV, RCV strains
do not target the liver or cause disease in rabbits, but lead to a localised, subclinical infection of
the small intestine [28,29]. Despite these significant differences in the viral pathology, the genome
organisation and the amino acid sequences of pathogenic and non-pathogenic viruses are very similar;
e.g. the RHDV and RCV RdRps, key enzymes in the replication cycle of rabbit caliciviruses, show up
to 90% amino acid identity (Figure 1).
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Figure 1. Amino acid alignment of RHDV and RCV RdRps. The alignment compares RHDV Czech 
strain V351 (GenBank accession number KF594473.1) and RCV‐A1 (GenBank accession number 
EU871528.1) and was conducted with the BioEdit software. Conserved motifs (A–E, F1–F3) attributed 
to RdRps of single‐stranded positive‐sense RNA viruses [30] are shown in black boxes. 
In 2010, a new RHDV variant (RHDV2) that caused atypical RHD outbreaks among vaccinated 
[31] and young [32,33] rabbits emerged in France [31]. This is remarkable because both are usually 
refractory to lethal RHDV infection. The subsequent analysis of a series of RHDV2 full length 
genomes revealed multiple recombination events that share a common theme, i.e., all recombinants 
possessed the structural proteins of RHDV2 and the non‐structural proteins of either a non‐
pathogenic rabbit calicivirus strain or from a pathogenic genogroup 1 strain [34]. Since existing 
vaccines are based on “classic” strains, RHDV2 quickly disseminated throughout Europe, killing a 
high proportion of vaccinated animals in affected rabbitries [35]. The existing vaccines appeared at 
least partially effective against RHDV2 [32,36]. However, there was no guaranteed way of reliably 
protecting valuable breeding stock and pets in the years between the detection of this new emerging 
rabbit calicivirus variant and the development of a specific vaccine, which has only recently become 
available [37]. RHDV2 has now spread beyond Europe and has recently been reported in Australia 
[38], where the new RHDV2 vaccine is not available yet and farmed and pet rabbits are currently at 
risk from this new emerging RHDV variant. Antivirals that could effectively treat infected rabbits 
would represent a useful additional tool to control outbreaks in high value rabbit breeding 
enterprises, and would also help to treat valued family pets until new vaccines become available. 
The lack of an effective cell culture system for rabbit caliciviruses [2,39] prompted us to adopt 
cell‐free in vitro assays for testing inhibitors of the RdRp, a protein that represents a prime target for 
antiviral drug design due to its essential role in the virus replication cycle and the fact that eukaryotic 
cells do not possess closely related enzymes. Sequence similarities between the 3D RdRp of 
picornaviruses and the RHDV polyprotein cleavage product p58 suggest that both polypeptides have 
a similar role in genome replication [40,41]. Expression of the respective coding region in Escherichia 
coli (E. coli) showed that p58 is indeed an enzymatically active RdRp [40], and did not demonstrate 
DNA‐dependent RNA polymerase, reverse transcriptase or DNA‐dependent DNA polymerase 
activities [41]. Crystal structure of RHDV RdRp revealed that this enzyme adopts a shape that 
resembles a right hand, with domains corresponding to the fingers, palm and thumb, as seen in the 
three‐dimensional structures of many other polymerases [42]. In vitro activity assays demonstrated 
Figure 1. Amino acid alignment of RHDV and RdRps. The alignme t compares RHDV Czech
strain V351 (GenBank accession number KF594473.1) and RCV-A1 (GenBank accession number
EU871528.1) and was conducted with the BioEdit software. Conserved motifs (A–E, F1–F3) attributed
to RdRps of single-stranded positive-sense RNA viruses [30] are shown in black boxes.
In 2010, a new RHDV variant (RHDV2) that caused atypical RHD outbreaks among vaccinated [31]
and young [32,33] rabbits emerged in France [31]. This is remarkable because both are usually
refractory to lethal RHDV infection. The subsequent analysis of a series of RHDV2 full length genomes
revealed multiple recombination events that share a common theme, i.e., all recombinants possessed
the structural proteins of RHDV2 and the non-structural proteins of either a non-pathogenic rabbit
calicivirus strain or from a pathogenic genogroup 1 strain [34]. Since existing vaccines are based
on “classic” strains, RHDV2 quickly disseminated throughout Europe, killing a high proportion of
vaccinated animals in affected rabbitries [35]. The existing vaccines appeared at least partially effective
against RHDV2 [32,36]. However, there was no guaranteed way of reliably protecting valuable
breed ng stock and pe s in the years betwe n the detect on of this new merging rabbit calicivirus
variant and the development of a specific vaccine, which has only recently become available [37].
RHDV2 has now spread beyond Europe and has recently been reported in Australia [38], where the
new RHDV2 vaccine is not available yet and farmed and pet rabbits are currently at risk from this
new emerging RHDV variant. Antivirals that could effectively treat infected rabbits would represent a
useful additional tool to control outbreaks in high value rabbit breeding enterprises, and would also
help to treat valued family pets until new vacc nes become available.
The lack of an effective cell culture system for rabbit caliciviruses [2,39] prompted us to adopt
cell-free in vitro assays for testing inhibitors of the RdRp, a protein that represents a prime target
for antiviral drug design due to its essential role in the virus replication cycle and the fact that
eukaryotic cells do not possess closely related enzymes. Sequence similarities between the 3D RdRp
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of picornaviruses and the RHDV polyprotein cleavage product p58 suggest that both polypeptides
have a similar role in genome replication [40,41]. Expression of the respective coding region in
Escherichia coli (E. coli) showed that p58 is indeed an enzymatically active RdRp [40], and did not
demonstrate DNA-dependent RNA polymerase, reverse transcriptase or DNA-dependent DNA
polymerase activities [41]. Crystal structure of RHDV RdRp revealed that this enzyme adopts a shape
that resembles a right hand, with domains corresponding to the fingers, palm and thumb, as seen in
the three-dimensional structures of many other polymerases [42]. In vitro activity assays demonstrated
that recombinant RHDV RdRp was able to use (+) and (–) single-stranded RNA templates in the
absence of added primers and could synthesize subgenomic RNA by internal initiation of replication,
using a subgenomic promoter on a (–) strand genomic RNA template [43]. It has also been reported
that, in addition to its polymerase activity, p58 is able to catalyse VPg uridylylation [20].
In this study, recombinant RdRps from a pathogenic and a non-pathogenic rabbit caliciviruses
were tagged with a C-terminal hexahistidine, expressed in E. coli and purified by nickel affinity
chromatography. Basic enzyme characteristics (effects of temperature, MnCl2 concentration, pH
and substrate concentrations) and the inhibitory effects of several non-nucleoside inhibitors (NNIs)
were studied. These NNIs were previously identified through high-throughput screening as human
norovirus (NoV) RdRp inhibitors [44].
Taking into account the recombination events that led to the evolution of RHDV2 [34], RdRps from
both pathogenic and non-pathogenic strains were included in the study to identify compound(s) that
can suppress both viral enzymes and thus can be potentially effective against any new RHDV variants.
2. Materials and Methods
2.1. Plasmids
RHDV RNA was purified from a commercial RHDV suspension (Czech strain V351, GenBank
accession number KF594473.1, Elizabeth Macarthur Agricultural Institute, Menangle, Australia); RCV
RNA was purified from the homogenised small intestine of a rabbit infected with the non-pathogenic
calicivirus RCV-A1 (GenBank accession number EU871528.1) [28] using the RNeasy Mini Kit (Qiagen,
Hilden, Germany). Viral RNA was converted into cDNA using SuperScript III reverse transcriptase
(Life Technologies, Carlsbad, CA, USA). The cDNAs encoding viral RdRps were amplified using
Q5 High-Fidelity DNA polymerase (New England BioLabs, Ipswich, MA, USA) and gene-specific
primers (GeneWorks; for sequence information see Table 1), according to the instructions of the
manufacturer. Resulting amplicons were cloned into the pET-26b(+) expression vector (Novagen,
Darmstadt, Germany) to generate recombinant polymerases with a C-terminal His6-tag using the
following strategy. PCR products were digested using the XhoI restriction enzyme (New England
BioLabs). The pET-26b(+) expression vector was linearised using the NdeI restriction enzyme (New
England BioLabs), 5’ overhangs were filled in using T4 DNA polymerase (Promega, Madison, WI,
USA) to generate a blunt end and was further digested using the XhoI restriction enzyme. All inserts
were ligated into linearised vectors using the T4 DNA ligase (New England BioLabs).
NoV GII.4 Sydney 2012 RNA (NoV NSW028D/January/2013, GenBank accession number
KT239579) was purified from a clinical stool sample, converted into cDNA, amplified and cloned into
the pGEM-T-easy vector. The full length coding sequence of NoV GII.4 RdRp was amplified from
the resulting plasmid using gene-specific primers (Table 1) and subsequently cloned into pET-26b(+)
expression vector using NdeI (5’ terminus) and XhoI (3’ terminus) restriction sites.
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Table 1. Sequences of primer pairs for generation of expression constructs.
Construct Name Primer Sequence (5’Ñ3’) a
RdRp (RHDV)_His6
F: ATGACGTCAAACTTCTTCTGTGG
R: TATCCTCGAGCTCCATAACATTCACAAATTCGTC
RdRp (RCV)_His6
F: ATGACTGCAAACTTCTTCTGTG
R: TATCCTCGAGCTCCATAACATTCACAAAATCGTC
RdRp (NoV)_His6
F: TTTAAGAAGGAGATATACATATGGGAGGTGACAGTAAAGGGAC
R: CAGTGGTGGTGGTGGTGGTGCTCGAGCTCGACGCCATCTTCATTC
a RHDV Czech strain V351, RCV-A1 MIC-07 and NoV NSW028D/January/2013 genome sequences (GenBank
accession numbers KF594473.1, EU871528.1 and KT239579, respectively) were used to design primers for PCR
amplification. F—forward primer; R—reverse primer. NdeI and XhoI restriction sites are underlined. Initiation
codon sequences are shown in bold.
2.2. Compounds
Compounds that were tested in the study: NIC02 (a phenylthiazole-5-carboxamide), NIC10
(a triazole), NIC12 (a pyrazolidine-3,5-dione) (Figure 2) and NIC12 derivatives (NIC12-2, NIC12-3,
NIC12-4, NIC12-5) were described previously [44].
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2.3. Protein Expression and Purification
The constructs encoding His6-tagged RdRps were transformed into E. coli BL21(DE3) cells
(BioLabs). Selected colonies were suspended in 10 mL of Luria-Bertani (LB) medium with 50 µg/mL
kanamycin (Sigma-Aldrich, St. Louis, MO, USA) and incubated at 37 ˝C, in an orbital shaker at
200 r.p.m. for 6 h. Prepared cultures (10 mL) were inoculated into 500 mL of LB-kanamycin medium
and incubated at 37 ˝C, 200 r.p.m., until the OD600 reached 0.5. Expression of the RdRps was induced
with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) (Sigma-Aldrich) and the culture was further
incubated at 25 ˝C overnight. Cells were collected by centrifugation and the bacterial pellet was stored
at ´80 ˝C until use.
For RdRp purification, bacterial pellets were resuspended in 1ˆ CelLytic™ B buffer
(Sigma-Aldrich) containing 25 mM Tris-HCl (pH 8), 50 mM NaCl (for RHDV/RCV RdRps) or
10 mM NaCl (for NoV RdRp), 100 mg/mL of lysozyme (Sigma-Aldrich), 50 U/mL of Benzonase®
(Sigma-Aldrich), 2 mM MgCl2, 4 µg/mL RNase A (Sigma-Aldrich), and 1ˆ ethylenediaminetetraacetic
acid (EDTA)-free protease inhibitor cocktail solution (Sigma-Aldrich). Resuspended cells were
incubated at room temperature for 30 min with shaking to allow for chemical lysis. After lysis,
NaCl concentration was adjusted to 300 mM NaCl (RHDV/RCV RdRps) and lysates were clarified by
centrifugation at 4 ˝C. The clarified lysate was loaded onto Ni2+ columns pre-equilibrated with loading
buffer containing 25 mM Tris-HCl (pH 8), 300 mM (RHDV/RCV RdRps) or 500 mM (NoV RdRp) NaCl,
and 0.2% octyl-P-glucoside (Sigma-Aldrich). Once bound, the columns were washed with loading
buffer and then wash buffer containing 25 mM Tris-HCl (pH 8), 300 mM (RHDV/RCV RdRps) or
500 mM (NoV RdRp) NaCl, 0.1% octyl-P-glucoside and 10 mM (RHDV/RCV RdRps) or 5 mM (NoV
RdRp) of imidazole. The RdRps were then eluted by increasing the imidazole concentration from
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10 mM (RHDV/RCV RdRp) or 5 mM (NoV RdRp) to 300 mM (RHDV/RCV RdRp) or 500 mM (NoV
RdRp). The purified RdRps were dialysed and stored in a buffer containing 150 mM NaCl, 50 mM
Tris-HCl (pH 8.0), 10 mM MgCl2 (RHDV/RCV RdRps) or 150 mM NaCl, 25 mM Tris-HCl (pH 7.5),
1 mM EDTA, 1 mM dithiothreitol (DTT) (NoV RdRp) and 20% glycerol at ´80 ˝C. The purity of
RdRps was confirmed by SDS-PAGE. Protein concentration was estimated with a Nanodrop ND-1000
spectrophotometer (the protein A280 method).
2.4. Kinetics of RdRp Activity
Main RdRp activity was quantified by monitoring the formation of double-stranded RNA (dsRNA)
from a single-stranded homopolymeric template, poly(C) (Sigma-Aldrich), using the fluorescent dye
PicoGreen (Life Technologies), as described previously [45] with minor modifications. Briefly, RdRp
activity assays were performed in 25-µL reactions. A standard reaction contained 20 ng/µL poly(C)
RNA (Sigma-Aldrich), 0.5 mM rGTP (Promega), 2.5 mM MnCl2, and 5 mM DTT in 20 mM Tris-HCl
(pH 7.5) buffer. Reactions were initiated by the addition of 20–40 ng RdRp and incubated at 30 ˝C for
15 min unless stated otherwise. Reactions were terminated with 5 mM EDTA, followed by PicoGreen
staining and dsRNA quantitation using either POLARstar or SpectraMax M3 plate readers at standard
wavelengths (excitation 480 nm, emission 520 nm). Control reactions stopped at 0 min were used to
quantify background fluorescence.
The optimum conditions for RdRp activities were examined by titrating enzyme concentrations,
incubation time, concentration of MnCl2 (0–10 mM), varying pH (7.0–9.5, 20 mM Tris-HCl) and reaction
temperatures (4–60 ˝C). To evaluate the kinetics of nucleotide incorporation by the RCV and RHDV
RdRps, reactions were run with 40 ng of enzyme, 2.5 mM MnCl2, 5 mM DTT and 20 ng/µL poly(C) in
20 mM Tris-HCl (pH 7.5) buffer for 15 min at 30 ˝C with increasing rGTP concentrations (0–2.0 mM).
To evaluate the kinetics of the poly(C) template utilisation, reactions were run with 40 ng of enzyme,
2.5 mM MnCl2, 5 mM DTT and 0.5 mM rGTP substrate in 20 mM Tris-HCl buffer (pH 7.5) for 15 min
at 30 ˝C with increasing poly(C) concentrations (0–80 ng/µL).
2.5. Quantitative RdRp Assays to Test Non-Nucleoside Inhibitors (NNI)
RdRp assays were performed in 384-well plates, as described previously [45]. A single 25-µL
reaction mixture contained 20–400 ng enzyme, 45 µM rGTP, 10 ng/µL poly(C) RNA, 2.5 mM MnCl2,
5 mM DTT, 0.01% bovine serum albumin (BSA), and 0.005% Tween 20 in 20 mM Tris-HCl (pH 7.5).
RdRps were incubated for 10 min at 30 ˝C in the presence of the test compounds or the compound
vehicle DMSO (0.5% v/v) before addition into the reaction mixture. The reaction was then allowed to
proceed for 15 min at 30 ˝C. The reaction was terminated with 5 mM EDTA, followed by PicoGreen
staining and dsRNA quantitation using a POLARstar plate reader at standard wavelengths (excitation
480 nm, emission 520 nm).
2.6. Gel-Based RdRp Assays
Denaturing polyacrylamide gel-based assays were used to examine the primer extension activity
of the RdRps, using a previously described method [46] with modifications. The original template
PE46 was modified to replace 13 nucleotides at the 5’ end with 13 cytosines, resulting in a new template
PE46-C. The new template PE46-C (5’-CCCCCCCCCCCCCCCAUAUACUUCGGUAUAUGG-3’) was
used to direct primer extension activity through a stable hairpin at the 3’ end. Reactions were performed
using 1 µM PE46-C template and 400 ng RdRp, 0.4 mM rGTP (Promega), 5 mM DTT, 2.5 mM MnCl2,
and 20 mM Tris-HCl (pH 7.5) in a final volume of 25 µL. RdRps were incubated for 10 min at 30 ˝C
in the presence of the test compounds or the compound vehicle DMSO (0.5% v/v) prior to addition
into the reaction mixture. Reaction mixtures were then incubated for 6 h at 30 ˝C. RNA products
were analysed on 15% denaturing polyacrylamide gels containing 7 M urea (Bio-Rad, Hercules, CA,
USA). Gels were stained with SYBR green II (Invitrogen) and visualised on a Gel Doc molecular
imager (Bio-Rad).
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2.7. Data Analysis
Amino acid alignments were conducted with BioEdit software. Enzyme kinetics data were
analysed and graphs were generated using Graphpad Prism software (version 6.05).
3. Results
3.1. RdRp Expression and Characterisation
To investigate the biochemical properties of rabbit calicivirus RdRps and to test potential
inhibitors, the entire RdRp coding regions from a pathogenic RHDV strain (Czech V351) and that
of a non-pathogenic RCV strain (RCV-A1) were cloned into a bacterial expression vector, which
allowed the production of recombinant proteins with a C-terminal leucine-glutamic acid followed by a
hexahistidine tag to facilitate nickel affinity purification. The identity and quality of the purified
proteins was confirmed by SDS-PAGE, Western blot and tandem mass spectrometry of tryptic
peptides [47] (data not shown).
To characterise the kinetic properties of RHDV and RCV-A1 RdRps and to compare the
performance of these polymerases with that of other virus polymerases (e.g., human NoV RdRp),
polymerase activities were measured using a fluorescence-based in vitro assay under a variety
of conditions, including different pH, temperature, MnCl2 concentration, template and substrate
concentrations. Interestingly, the in vitro polymerase activity of the RCV enzyme was at least two times
higher than that of the RHDV RdRp activity (Figure 3).
Viruses 2016, 8, 100 7 of 16 
 
 c r t   i      ‐       
          . .,   , 
 i iti  ere measured using a fluorescence‐based in vitro assay under a variety of 
conditions, including differ nt pH, temperature, MnCl2 concentration, te plate   
tr tions. Interestingly, the in vitro polymerase activity of the RCV enzyme was a  leas  two 
times higher than that of the RHDV RdRp activity (Figure 3). 
 
Figure 3. Comparison of RHDV and RCV RdRp activities. Purified recombinant RdRps were used to 
generate dsRNA from a poly(C) RNA (20 ng/μL) template using rGTP (0.5 mM) as substrate. 
Following incubation at 30 °C, reactions were stopped with 5 mM EDTA and dsRNA was quantified 
using the fluorescent dye PicoGreen. RHDV RdRp activity is shown in red, RCV RdRp activity is 
shown in blue. The results from a representative experiment are shown with average values and 
standard deviations from triplicate reactions for each measurement point. (a) The effect of RHDV and 
RCV RdRp concentrations on dsRNA formation over 15 min; (b) The synthesis of dsRNA catalysed 
by 20 ng of RHDV and RCV RdRps over a 1‐h period. RFU—relative fluorescence units. 
To determine the optimal concentration of MnCl2 for the de novo RdRp activity on a poly(C) RNA 
template, RdRp assays with MnCl2 concentrations ranging from 0 to 10 mM were conducted. RdRp 
activities increased with increasing concentrations of MnCl2 in the range 0 to 2.5 mM and reached a 
plateau at higher concentrations (Figure 4a). RCV and RHDV RdRp activities were also tested with 
20 mM Tris‐HCl reaction buffers adjusted to pH 7.0, 7.5, 8.0, 8.5, 9.0 and 9.5. Both RHDV and RCV 
RdRps showed the highest activities at pH 8.5. Compared to NoV RdRp, that showed similar 
activities at pH ranging from 7.0 to 8.0, the pH optimum for RHDV and RCV RdRps activities were 
found to be highest at the relatively basic value of pH 8.5 (Figure 4b). Next we assessed RCV and 
RHDV RdRps for de novo polymerase activity at different temperatures ranging from 4 °C to 50 °C. 
Compared to NoV RdRp, that showed the highest activities between 35 and 39 °C, rabbit calicivirus 
RdRps were more active at higher temperatures. Both RdRps showed the highest activities between 
40 and 45 °C. Strong activities, approximately 50% and more of the highest values, were exhibited by 
both enzymes at temperatures ranging from 30 to 50 °C (Figure 4c). 
To evaluate the kinetics of template utilisation, reactions were run with increasing poly(C) 
concentrations (0–40 ng/μL). The results were in general agreement with the Michaelis‐Menten model 
for enzyme kinetics. That is, RdRp activities went up with increasing concentrations of poly(C) in the 
range of 0 to 10 ng/μL and reached a plateau at higher concentrations (Figure 5a). To examine the 
kinetics of nucleotide incorporation by the RCV and RHDV RdRps, reactions were run with 
increasing rGTP concentrations (0–2.0 mM). Interestingly, in contrast to poly(C) template utilisation, 
the kinetics of rGTP polymerisation in the given range deviated from standard Michaelis‐Menten 
kinetics. RdRp activities increased sharply in the range of 0 to 0.1 mM, plateaued between 0.1 and 0.5 
mM and decreased at higher substrate concentrations (Figure 5b,c). Kinetic data for RHDV, RCV and 
NoV RdRps are shown in Table 2. 
Figure 3. Comparison of RHDV and RCV RdRp activities. Purified recombinant RdRps were used to
generate dsRNA from a poly(C) RNA (20 ng/µL) template using rGTP (0.5 mM) as substrate. Following
incubation at 30 ˝C, reactions were stopped with 5 mM EDTA and dsRNA was quantified using the
fluorescent dye PicoGreen. RHDV RdRp activity is shown in red, RCV RdRp activity is shown in
blue. The results from a representative experiment are shown with average values and standard
deviations from triplicate reactions for each measurement point. (a) The effect of RHDV and RCV
RdRp concentrations on dsRNA formation over 15 min; (b) The synthesis of dsRNA catalysed by 20 ng
of RHDV and RCV RdRps over a 1-h period. RFU—relative fluorescence units.
To determine the optimal concentration of MnCl2 for the de novo RdRp activity on a poly(C) RNA
template, RdRp assays with MnCl2 concentrations ranging from 0 to 10 mM were conducted. RdRp
activities increased with increasing concentrations of MnCl2 in the range 0 to 2.5 mM and reached a
plateau at higher concentrations (Figure 4a). RCV and RHDV RdRp activities were also tested with
20 mM Tris-HCl reaction buffers adjusted to pH 7.0, 7.5, 8.0, 8.5, 9.0 and 9.5. Both RHDV and RCV
RdRps showed the highest activities at pH 8.5. Compared to NoV RdRp, that showed similar activities
at pH ranging from 7.0 to 8.0, the pH optimum for RHDV and RCV RdRps activities were found to be
highest at the relatively basic value of pH 8.5 (Figure 4b). Next we assessed RCV and RHDV RdRps
for de novo polymerase activity at different temperatures ranging from 4 ˝C to 50 ˝C. Compared to
NoV RdRp, that showed the highest activities between 35 and 39 ˝C, rabbit calicivirus RdRps were
more active at higher temperatures. Both RdRps showed the highest activities between 40 and 45 ˝C.
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Strong activities, approximately 50% and more of the highest values, were exhibited by both enzymes
at temperatures ranging from 30 to 50 ˝C (Figure 4c).Viruses 2016, 8, 100 8 of 16 
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To evaluate the kinetics of template utilisation, reactions were run with increasing poly(C)
concentrations (0–40 ng/µL). The results were in general agreement with the Michaelis-Menten
model for enzyme kinetics. That is, RdRp activities went up with increasing concentrations of poly(C)
in the range of 0 to 10 ng/µL and reached a plateau at higher concentrations (Figure 5a). To examine
the kinetics of nucleotide incorporation by the RCV and RHDV RdRps, reactions were run with
increasing rGTP concentrations (0–2.0 mM). Interestingly, in contrast to poly(C) template utilisation,
the kinetics of rGTP polymerisation in the given range deviated from standard Michaelis-Menten
kinetics. RdRp activities increased sharply in the range of 0 to 0.1 mM, plateaued between 0.1 and
0.5 mM and decreased at higher substrate concentrations (Figure 5b,c). Kinetic data for RHDV, RCV
and NoV RdRps are shown in Table 2.
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Figure 5. Kinetics of template and substrate utilisation by calicivirus RdRps. Purified recombinant
RdRps (40 ng of RHDV and RCV RdRps and 200 ng of NoV RdRp) were used to generate dsRNA
with poly(C) RNA as template and rGTP as substrate. (a) The kinetics of template utilisation was
examined by titrating poly(C) from 0 to 40 ng/µL in the presence of 0.5 mM rGTP; (b,c) The kinetics of
nucleotide incorporation was examined by titrating rGTP from 0 to 0.5 mM and 0 to 2.0 mM in the
presence of 20 ng/µL of poly(C). Following a 15-min incubation at 30 ˝C, reactions were stopped with
EDTA at final concentration 5 mM and dsRNA was quantified using the PicoGreen reagent. RHDV
RdRp activity is shown in red as triangles, RCV RdRp activity is shown in blue as squares and NoV
RdRp activity is shown in black as circles. The results from a representative experiment are shown
with average values and standard deviations from triplicate reactions for each measurement point.
Table 2. Kinetic analysis of the RHDV, RCV and NoV RdRps.
Biochemical Property RHDV RdRp RCV RdRp NoV RdRp
Vmax (pg(dsRNA) ˆmin ´1 ˆ ng(RdRp) ´1) at 30 ˝C 4.0 ˘ 0.4 13.4 ˘ 1.5 4.1 ˘ 0.6
Vmax (pg(dsRNA) ˆmin ´1 ˆ ng(RdRp) ´1) at 42 ˝C
(RHDV/RCV) or 37 ˝C (NoV) 6.6 ˘ 0.6 30.3 ˘ 1.3 5.8 ˘ 0.3
Km (poly(C)) (ng/µL) at 30 ˝C 0.5 ˘ 0.1 0.9 ˘ 0.2 3.6 ˘ 0.6
Km (rGTP), Michaelis-Menten model (µM) at 30 ˝C 14.6 ˘ 2.4 5.7 ˘ 0.7 77.7 ˘ 14.5
Km (rGTP), substrate inhibition model (µM) at 30 ˝C 19.1 ˘ 3.8 8.0 ˘ 0.8 448.8 ˘ 120.4
Ki (rGTP), substrate inhibition model (mM) at 30 ˝C 2.1 ˘ 0.4 1.7 ˘ 0.2 0.6 ˘ 0.2
3.2. Testing of RdRp Inhibitors
Three NNIs, namely NIC02, NIC10, and NIC12 were previously shown to inhibit the RdRp of
NoV GII.4 (Den Haag 2006b variant) with the half-maximal inhibitory concentrations (IC50) of 5.0, 9.2
and 9.8 µM, respectively [44]. This prompted us to test these compounds against RCV and RHDV
RdRps. NIC02 inhibited the de novo polymerase activity of both RHDV and RCV enzymes with the
IC50 of 19.9 µM (95% CI: 9.1–57.0 µM) and 13.5 µM (95% CI: 10.9–29.0 µM), respectively (Figure 6). In
addition, we found that NIC02 also inhibited the primed elongation activity of RHDV and RCV RdRps
in a gel-based assay (Figure 7). Inhibition of RHDV RdRp by NIC02 is shown at 19.9 µM (IC50) and
99.5 µM (5ˆ IC50) and RCV RdRp by NIC02 at 13.5 µM (IC50) and 67.5 µM (5ˆ IC50). An attenuation
of dsRNA formation is observed at the IC50 for both RHDV and RCV RdRps, with no dsRNA product
visible at 5ˆ the IC50 of NIC02.
Viruses 2016, 8, 100 10 of 17
Viruses 2016, 8, 100 9 of 16 
 
Table 2. Kinetic analysis of the RHDV, RCV and NoV RdRps. 
Biochemical Property RHDV RdRp RCV RdRp NoV RdRp 
Vmax (pg(dsRNA) × min −1 × ng(RdRp) −1) at 30 °C 4.0 ± 0.4 13.4 ± 1.5 4.1 ± 0.6 
Vmax (pg(dsRNA) × min −1 × ng(RdRp) −1) at 42 °C 
(RHDV/RCV) or 37 °C (NoV) 
6.6 ± 0.6 30.3 ± 1.3 5.8 ± 0.3 
Km (poly(C)) (ng/μL) at 30 °C 0.5 ± 0.1 0.9 ± 0.2 3.6 ± 0.6 
Km (rGTP), Michaelis‐Menten model (μM) at 30 °C 14.6 ± 2.4 5.7 ± 0.7 77.7 ± 14.5 
Km (rGTP), substrate inhibition model (μM) at 30 °C 19.1 ± 3.8 8.0 ± 0.8 448.8 ± 120.4 
Ki (rGTP), substrate inhibition model (mM) at 30 °C 2.1 ± 0.4 1.7 ± 0.2 0.6 ± 0.2 
3.2. Testing of RdRp Inhibitors 
Three NNIs, namely NIC02, NIC10, and NIC12 were previously shown to inhibit the RdRp of 
NoV GII.4 (Den Haag 2006b variant) with the half‐maximal inhibitory concentrations (IC50) of 5.0, 9.2 
and 9.8 μM, respectively [44]. This prompted us to test these compounds against RCV and RHDV 
RdRps. NIC02 inhibited the de novo polymerase activity of both RHDV and RCV enzymes with the 
IC50 of 19.9 μM (95% CI: 9.1–57.0 μM) and 13.5 μM (95% CI: 10.9–29.0 μM), respectively (Figure 6). In 
addition, we found that NIC02 also inhibited the primed elongation activity of RHDV and RCV 
RdRps in a gel‐based assay (Figure 7). Inhibition of RHDV RdRp by NIC02 is shown at 19.9 μM (IC50) 
and 99.5 μM (5× IC50) and RCV RdRp by NIC02 at 13.5 μM (IC50) and 67.5 μM (5× IC50). An attenuation 
of dsRNA formation is observed at the IC50 for both RHDV and RCV RdRps, with no dsRNA product 
visible at 5× the IC50 of NIC02. 
 
Figure 6. NIC02 inhibits de novo polymerase activity of rabbit calicivirus RdRps in vitro. The inhibitory 
effects of NIC02 on the de novo activity of (a) RHDV; and (b) RCV RdRps were analysed by monitoring 
the formation of dsRNA from a single‐stranded poly(C) homopolymeric template. NIC02 
concentrations were varied between 0.1–100 μM and compared to the relative activity in mock‐treated 
samples containing the vehicle (0.5% v/v DMSO) only. Log (inhibitor concentration) vs. response 
curves were plotted. RHDV RdRp activity is shown in red as triangles, RCV RdRp activity is shown 
in blue as squares. Averages of relative fluorescence levels were calculated and plotted with standard 
deviations. Results from three independent experiments with triplicate reactions for each 
measurement point are shown. 
 
Fig re 6. NIC02 inhibits de novo polymerase activity of rabbit calicivirus RdRps in vitro. The
inhibit ry effects of NIC02 on the de novo activity of (a) RHDV; an (b) RCV RdRps were analysed by
monitoring the f rmation of dsRNA from a single-stranded poly(C) hom polymeric template. I
t ti i t . µ t t r l ti ti it i c -tr t
l c taining the vehicle (0.5% v/v DMSO) only. Log (inhibitor concentration) vs. respons curves
were plotted. RHDV dRp activity is shown in red as triangles, RCV RdRp activity is shown n blue as
squar s. Aver ges of r l tive fluorescence levels were calculated and plotted with s andard deviations.
Results from three independent experiments with triplicate reac ions for each measurement point
ar shown.
Viruses 2016, 8, 100 9 of 16 
 
Table 2. Kinetic analysis of the RHDV, RCV and NoV RdRps. 
Biochemical Property RHDV RdRp RCV RdRp NoV RdRp 
Vmax (pg(dsRNA) × min −1 × ng(RdRp) −1) at 30 °C 4.0 ± 0.4 13.4 ± 1.5 4.1 ± 0.6 
Vmax (pg(dsRNA) × min −1 × ng(RdRp) −1) at 42 °C 
(RHDV/RCV) or 37 °C (NoV) 
6.6 ± 0.6 30.3 ± 1.3 5.8 ± 0.3 
Km (poly(C)) (ng/μL) at 30 °C 0.5 ± 0.1 0.9 ± 0.2 3.6 ± 0.6 
Km (rGTP), Michaelis‐Menten model (μM) at 30 °C 14.6 ± 2.4 5.7 ± 0.7 77.7 ± 14.5 
Km (rGTP), substrate inhibition model (μM) at 30 °C 19.1 ± 3.8 8.0 ± 0.8 448.8 ± 120.4 
Ki (rGTP), substrate inhibition model (mM) at 30 °C 2.1 ± 0.4 1.7 ± 0.2 0.6 ± 0.2 
3.2. Testing of RdRp Inhibitors 
Three NNIs, namely NIC02, NIC10, and NIC12 were previously shown to inhibit the RdRp of 
NoV GII.4 (Den Haag 2006b variant) with the half‐maximal inhibitory concentrations (IC50) of 5.0, 9.2 
and 9.8 μM, respectively [44]. This prompted us to test these compounds against RCV and RHDV 
RdRps. NIC02 inhibited the de novo polymerase activity of both RHDV and RCV enzymes with the 
IC50 of 19.9 μM (95% CI: 9.1–57.0 μM) and 13.5 μM (95% CI: 10.9–29.0 μM), respectively (Figure 6). In 
addition, we found that NIC02 also inhibited the primed elongation activity of RHDV and RCV 
RdRps in a gel‐based assay (Figure 7). Inhibition of RHDV RdRp by NIC02 is shown at 19.9 μM (IC50) 
and 99.5 μM (5× IC50) and RCV RdRp by NIC02 at 13.5 μM (IC50) and 67.5 μM (5× IC50). An attenuation 
of dsRNA formation is observed at the IC50 for both RHDV and RCV RdRps, with no dsRNA product 
visible at 5× the IC50 of NIC02. 
 
Figure 6. NIC02 inhibits de novo polymerase activity of rabbit calicivirus RdRps in vitro. The inhibitory 
effects of NIC02 on the de novo activity of (a) RHDV; and (b) RCV RdRps were analysed by monitoring 
the formation of dsRNA from a single‐stranded poly(C) homopolymeric template. NIC02 
concentrations were varied between 0.1–100 μM and compared to the relative activity in mock‐treated 
samples containing the vehicle (0.5% v/v DMSO) only. Log (inhibitor concentration) vs. response 
curves were plotted. RHDV RdRp activity is shown in red as triangles, RCV RdRp activity is shown 
in blue as squares. Averages of relative fluorescence levels were calculated and plotted with standard 
deviations. Results from three independent experiments with triplicate reactions for each 
measurement point are shown. 
 
Figure 7. NIC02 inhibits primed elongation activity of rabbit calicivirus RdRps in vitro. A gel-based
RdRp activity assay was used to evaluate effects of NIC02 on the primed elongation activity of RHDV
and RCV RdRps. (a) PE46-C template. (b) Products generated in the in the presence of 19.9 (IC50) and
99.5 µM (5ˆ IC50) NIC02 for RHDV RdRp, 13.5 (IC50) and 67.5 µM (5ˆ IC50) NIC02 for RCV RdRp
or in the presence of the vehicle (0.5% v/v DMSO) alone (no inhibitor). Products were separated on
a 15% denaturing polyacrylamide gel and stained with SYBR green II. Inhibition of the RdRp of Φ6
bacteriophage was carried out using 200 µM of the nucleoside analogue chain terminator 3’dGTP as an
inhibition control.
In contrast, NIC10 and NIC12, as well as four structural derivatives of NIC12 (NIC12-2, NIC12-3,
NIC12-4 and NIC12-5) showed only limited inhibitory effects on de novo RCV and RHDV RdRp activity
(Figure 8).
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Figure 8. Limited inhibitory effects of NIC10, NIC12 and NIC12 derivatives on de novo polymerase
activity of rabbit calicivirus RdRps in vitro. The effects of (a) NIC10; (b) NIC12 and the NIC12
derivatives; (c) NIC12-2; (d) NIC12-3; (e) NIC12-4; and (f) NIC-12-5 on the de novo activity of RHDV
and RCV RdRps were analysed by monitoring the formation of dsRNA. The chain terminator 3’dGTP
(10 µM) was used as a positive control (a,b). RHDV RdRp activity is shown in red, RCV RdRp
activity is shown in blue. The results are averages of relative fluorescence levels determined from
three independent experiments with triplicate reactions for each measurement point plotted with
standard deviations.
4. Discussion
4.1. RdRp Expression and Characterisation
One of the hallmarks of RHDV is its extreme virulence and the fast course of the acute fatal
disease (reviewed in [2]). Recent studies suggest that the virus is maintaining a high level of virulence
and replication speed that enables the virus to kill susceptible hosts within 2–3 days, before adaptive
immune responses develop [48]. In contrast, no pathogenicity has ever been observed in RCV-infected
rabbits, although studies describing RCV infections show that localised replication in the small intestine
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also progresses quickly and virus shedding can be observed from day 1 post infection [28]. It was
interesting to find that the in vitro polymerase activity of the non-virulent RCV RdRp was at least two
times higher compared to the RdRp of the highly virulent RHDV, although other enzyme characteristics
were very similar. An amino acid alignment of RHDV and RCV RdRps showed that they share up to
90% amino acid identity (Figure 1). However, it is notable that there are some amino acid substitutions
in motifs E and F that appear to be conserved among RdRps from other single-stranded positive-sense
RNA viruses [30,49,50]. It is a subject for further studies whether the observed differences in the
activity of RHDV and RCV RdRps can be explained by the presence of amino acid substitutions in the
E and F motifs (Figure 1). It is also presently unclear whether this interesting finding can be attributed
to the physiological conditions under which rabbit caliciviruses replicate in vivo. It is tempting to
speculate that the very high enzymatic activity of RCV RdRp is responsible for the high RCV genome
load in the duodenum of infected rabbits (up to 9.4 ˆ 106 RNA copies per mg of tissue) despite the
fact that only very few RCV antigen-positive epithelial cells can be detected in this tissue [29].
Previous studies have shown that RdRp fidelity can be a virulence determinant [51–53]. For the
highly pathogenic RHDV, a reduced RdRp activity may therefore represent a mechanism to increase
the fidelity of RNA synthesis, possibly assisting with maintaining very high levels of virulence in
RHDV [48]. Trade-offs between replication speed and fidelity are important factors that shape virus
evolution [54], and detailed comparative genetic studies of RCV-A1 and RHDV will be useful to assess
any differences in the evolutionary rates of these viruses. These future studies would greatly benefit
from in vitro studies that experimentally assess the fidelity of the two enzymes.
Our results revealed that salt requirements for in vitro activities of rabbit calicivirus RdRps are
similar to those of human and murine calicivirus RdRps [55]. These similarities, however, do not
extend to the pH requirements. In contrast to NoV RdRp that showed maximal activities between pH
7.0 and 8.0, rabbit calicivirus RdRps clearly prefer a more basic pH. This observation may be attributed
to the properties of the tissues/cells in which RHDV and RCV replicate. Both viruses show a tropism
for tissues involved in bicarbonate ion metabolism. The main replication site for RHDV is the liver, in
particular the periportal areas, while RCV replicates in the duodenum. Therefore, local/intracellular
pH in these tissues may be shifted towards a more basic pH [56–58].
A further unexpected result was that rabbit calicivirus RpRps are most active at temperatures
between 40 and 45 ˝C. This observation is different from published data for many other RdRps
that were found to work much more efficiently at lower temperatures (usually between 25 and
35 ˝C) [45,55,59–63]. However, it should be noted that, in our hands, NoV RdRp showed the
highest activity between 35 and 39 ˝C, which is also higher compared to the previously published
temperature optimum of 25 ˝C [55]. It should be further noted that our results were obtained using a
fluorescence-based assay, whereas radioactive assays were used in earlier studies [55], a difference
that may explain the observed discrepancies. It is generally accepted that viruses adapt to their
hosts, so it should not be surprising if the optimal temperature for viral enzymes lie within the range
of physiological temperatures observed in an infected host organism. Thus, the observed optimal
in vitro temperatures for the NoV RdRp (35–39 ˝C) and rabbit calicivirus RdRps (40–45 ˝C) may reflect
an adaptation to hosts with a body temperature of 37 ˝C (human) and more than 38 ˝C (rabbit),
respectively. If our observation is indeed relevant to in vivo conditions, it can be speculated that the
onset of fever (up to 42 ˝C [28]) during RHDV infection does not slow down virus replication.
The kinetics of the poly(C) template usage by both rabbit calicivirus RdRps tested in this study
were in agreement with the Michaelis-Menten model for enzyme kinetics, while the kinetics of rGTP
incorporation deviated from this model. Although in the range of substrate concentrations from 0
to 0.5 mM the results fit the Michaelis-Menten model, at higher substrate concentrations, a decrease
in enzyme activity was observed. This phenomenon is referred to as substrate inhibition and is
often interpreted as an abnormality that comes from using artificially high substrate concentrations
in in vitro assays. However, examples that substrate inhibition can be a biologically relevant
regulatory mechanism have been reported for a number of enzymes, such as tyrosine hydroxylase,
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acetylcholinesterase, DNA methyltrasferase, etc. [64,65]. Interestingly, rGTP concentrations in
rabbit cells (estimations vary between 200 to 700 µM) [66,67] are slightly higher than the optimum
concentration for maximum enzyme velocity, which supports the notion that these enzymes may
operate under “substrate inhibition” conditions in vivo. A similar substrate inhibition phenomenon
has previously been reported for other virus polymerases, including those of poliovirus [60], human
immunodeficiency virus type 1 (HIV-1) [68] and hepatitis C virus (HCV) [69]. Notably, all these
enzymes share a number of conserved motifs with rabbit calicivirus RdRps and seem to be structurally
very similar [30]. Moreover, it was shown that, in case of the HCV RdRp, rGTP has a second low-affinity
binding site outside the catalytic centre and it has been suggested that high rGTP concentrations
suppress primer-dependent RNA synthesis and stimulate de novo RNA synthesis [69–71]. A similar
mechanism, in which dNTPs act as non-competitive inhibitors, was proposed for the reverse
transcriptase of HIV-1 [68]. For these enzymes, it is likely that substrate inhibition is a property
that has evolved due to the fact that they have specialised sites where a second substrate molecule can
bind and act as an allosteric regulator [65]. Considering the very conservative nature of viral RdRps [30],
a similar regulatory role of rGTP may be proposed for rabbit calicivirus RdRps. It can be further
speculated that a slower recovery of active enzymes due to substrate inhibition [64] may represent a
speed-limiting mechanism to increase the fidelity of RNA synthesis thereby preventing a so-called
“error catastrophe”, an outcome in which a genetic element cannot be maintained in a population as the
fidelity of its replication machinery decreases beyond a certain threshold value [51,72–74]. The analysis
of substrate inhibition, irrespective of whether it occurs under physiological or non-physiological
conditions, can provide important insights into the functioning and regulation of enzymes [64].
4.2. Testing of RdRp Inhibitors
Eltahla et al. [45] and Yi et al. [46] demonstrated that in vitro fluorescence-based and gel-based
polymerase activity assays can be used for the initial screening and testing of small compound
inhibitors against positive-sense RNA viruses that cannot be grown in cell culture [44–46]. In this
study, a total of seven potential rabbit calicivirus antivirals were tested.
NIC02 demonstrated inhibitory activity in the low micromolar range against rabbit calicivirus
RdRps and can be considered as a scaffold for further development of therapeutic molecules against
RHDV. NIC02 was previously reported as a viral NNI with no substantial effect on an RNA-dependent
DNA polymerase (from avian myeloblastosis virus) and a DNA-dependent DNA polymerase (Taq
polymerase). NIC02 demonstrated mixed mechanism of inhibition and activity against various species
within the Norovirus and Sapovirus genera of the Caliciviridae family, and it has been suggested that
such a broad inhibitory activity spectrum could be explained by putative binding of NIC02 to a highly
conserved motif of calicivirus RdRps. NIC02 inhibitory effect on NoV replication was also validated in
available cell culture systems (murine norovirus and GI.1 NoV replicon) [44].
In contrast to NIC02, the other six compounds that were tested against RCV and RHDV RdRps,
namely NIC10, NIC12, NIC12-2, NIC12-3, NIC12-4 and NIC12-5 (all structural derivatives of NIC12)
showed only modest or no inhibitory activities. These findings are in agreement with a previous study
in which the inhibitory profiles of NIC10 and NIC12 were found to be restricted to particular RdRps
from certain human NoV species [44].
5. Conclusions
The sudden emergence of RHDV2, a variant that could overcome protection afforded by existing
vaccines, and the likely risk that even more virulent RHDV variants may emerge over time, highlight
the need to develop alternative approaches to protect valued rabbit stocks and pets. The availability
of effective antiviral agents against a broad range of RHDV variants would enable rabbit farmers to
prevent/control RHD outbreaks more effectively. Using fluorescence-based and gel-based in vitro
polymerase assays, we have identified NIC02 as a compound with inhibitory activity in the low
micromolar range against rabbit calicivirus RdRps. NIC02 can be explored further as a potential
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scaffold in order to design a potent NNI capable of combating RHDV infections. Moreover, our results
revealed a number of interesting properties of the RHDV and RCV RdRps that may help to better
understand some of the unique characteristics of rabbit calicivirus pathobiology.
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